Jennifer Harrington1, Abdulmajeed AlSubaihin2, Lucie Dupuis3, Peter Kannu3, Roberto Mendoza-Londono3, Andrew Howard4. 1. Division of Endocrinology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada. jenny.harrington@sa.gov.au. 2. Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia. 3. Division of Clinical and Metabolic Genetics, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada. 4. Division of Orthopedics, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
Abstract
We assessed the diagnostic utility of genetic panel testing to detect pathogenic variants associated with osteogenesis imperfecta in children presenting with multiple fractures. Thirty-five percent of children had a pathogenic variant. A history of a femur fracture or a first fracture occurring under 2 years of age were significant clinical predictors. PURPOSE: The use of next-generation sequencing (NGS) genetic panels offers a comprehensive rapid diagnostic test to evaluate for pathogenic variants in the expanding list of genes associated with osteogenesis imperfecta (OI). We aimed to assess the diagnostic utility of this method in children with a clinically significant fracture history. METHODS: NGS panel testing was performed in 87 children presenting with multiple long bone or vertebral fractures. Subjects with a known family history of OI were excluded. Associations between genetic findings and clinical characteristics were analyzed in a retrospective observational study. RESULTS: Thirty-five percent of patients were found to have a disease-causing variant, with a higher detection rate in those patients with extra-skeletal features of OI (94 vs. 20%, p < 0.001). In subjects with extra-skeletal clinical OI features, 69% were found to have pathogenic variants in COL1A1 or COL1A2. In children without extra-skeletal features, 14 of 70 (20%) had pathogenic variants, of which 7 were variants in type 1 collagen, and the remaining 7 variants were associated with osteoblast function or signaling (PLS3, SP7, LRP5). Clinical predictors for detecting a disease-causing variant included a history of having a first fracture that occurred under 2 years of age (Odds ratio 5.5, 95%CI 1.8, 16.9) and a history of a femur fracture (Odds ratio 3.3, 95%CI 1.0, 11.1). CONCLUSION: NGS panel testing will detect causative pathogenic variants in up to a third of children with a clinically significant fracture history, particularly where there is a history of early femur fracture.
We assessed the diagnostic utility of genetic panel testing to detect pathogenic variants associated with osteogenesis imperfecta in children presenting with multiple fractures. Thirty-five percent of children had a pathogenic variant. A history of a femur fracture or a first fracture occurring under 2 years of age were significant clinical predictors. PURPOSE: The use of next-generation sequencing (NGS) genetic panels offers a comprehensive rapid diagnostic test to evaluate for pathogenic variants in the expanding list of genes associated with osteogenesis imperfecta (OI). We aimed to assess the diagnostic utility of this method in children with a clinically significant fracture history. METHODS: NGS panel testing was performed in 87 children presenting with multiple long bone or vertebral fractures. Subjects with a known family history of OI were excluded. Associations between genetic findings and clinical characteristics were analyzed in a retrospective observational study. RESULTS: Thirty-five percent of patients were found to have a disease-causing variant, with a higher detection rate in those patients with extra-skeletal features of OI (94 vs. 20%, p < 0.001). In subjects with extra-skeletal clinical OI features, 69% were found to have pathogenic variants in COL1A1 or COL1A2. In children without extra-skeletal features, 14 of 70 (20%) had pathogenic variants, of which 7 were variants in type 1 collagen, and the remaining 7 variants were associated with osteoblast function or signaling (PLS3, SP7, LRP5). Clinical predictors for detecting a disease-causing variant included a history of having a first fracture that occurred under 2 years of age (Odds ratio 5.5, 95%CI 1.8, 16.9) and a history of a femur fracture (Odds ratio 3.3, 95%CI 1.0, 11.1). CONCLUSION: NGS panel testing will detect causative pathogenic variants in up to a third of children with a clinically significant fracture history, particularly where there is a history of early femur fracture.
Authors: Nick Bishop; Paul Arundel; Emma Clark; Paul Dimitri; Joshua Farr; Graeme Jones; Outi Makitie; Craig F Munns; Nick Shaw Journal: J Clin Densitom Date: 2014-03-14 Impact factor: 2.617
Authors: Babette S Zemel; Heidi J Kalkwarf; Vicente Gilsanz; Joan M Lappe; Sharon Oberfield; John A Shepherd; Margaret M Frederick; Xiangke Huang; Ming Lu; Soroosh Mahboubi; Thomas Hangartner; Karen K Winer Journal: J Clin Endocrinol Metab Date: 2011-09-14 Impact factor: 5.958
Authors: David A Stevenson; John C Carey; Janice L B Byrne; Sivithee Srisukhumbowornchai; Marcia L Feldkamp Journal: Am J Med Genet A Date: 2012-03-27 Impact factor: 2.802
Authors: Cyrus Cooper; Elaine M Dennison; Herbert G M Leufkens; Nicholas Bishop; Tjeerd P van Staa Journal: J Bone Miner Res Date: 2004-09-20 Impact factor: 6.741
Authors: Joan C Marini; Antonella Forlino; Hans Peter Bächinger; Nick J Bishop; Peter H Byers; Anne De Paepe; Francois Fassier; Nadja Fratzl-Zelman; Kenneth M Kozloff; Deborah Krakow; Kathleen Montpetit; Oliver Semler Journal: Nat Rev Dis Primers Date: 2017-08-18 Impact factor: 52.329